WBR0458: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor={{Rim}}, {{Alison}}
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Pathology
|MainCategory=Pathology
Line 20: Line 20:
|MainCategory=Pathology
|MainCategory=Pathology
|SubCategory=Hematology, Oncology
|SubCategory=Hematology, Oncology
|Prompt=A 24 year old male patient presents to the physician’s office complaining of fatigue, unremitting fever, and easy bruisability with minor trauma.   His vital signs show a temperature of 38.6 degrees C (101.5 degrees F), heart rate of 98 beats per minute, and blood pressure measuring 116/82 mmHg.  His physical examination was remarkable for pallor, bleeding gums, and purpura.  An image of the patient’s peripheral blood smear is shown below.  Following the initiation of appropriate treatment, the patient suffers a complication.  Which of the following best characterized the patient’s complication?
|Prompt=A 24-year-old male patient to the physician’s office with complaints of fatigue, unremitting fever, and easy bruisability upon minor trauma. His vital signs demonstrate a temperature of 38.6 °C, heart rate of 98 beats per minute, and blood pressure measuring 116/82 mmHg.  Upon physical examination, you observe pallor, bleeding gums, and purpura.  An image of the patient’s peripheral blood smear is displayed below.  Following the initiation of appropriate treatment, the patient suffers a complication.  Which of the following best characterizes the patient’s complication?


[[Image:Auer_Rod.JPG|400px]]
[[Image:Auer_Rod.JPG|400px]]
|Explanation=[[Image:WBR Auer Rods Sign.jpg|400px]]  
|Explanation=[[Image:WBR Auer Rods Sign.jpg|400px]]  
The patient is presenting with [[acute promyelocytic leukemia]] ([[APML]]) or [[AML M3]].  Symptoms of [[AML M3]] are typically unremitting fever with signs of [[pancytopenia]]: [[Anemia]] as manifested by pallor, [[thrombocytopenia]] as manifested by easy bruisibility and [[purpura]], and [[leucopenia]] as manifested by [[sore throat]], [[pneumonia]], or other infections.  On peripheral smear, [[AML M3]] is characterized by [[Auer rods]].  The image above shows one [[Auer rod]] in circle; the image contains several other examples that are not circled.  Treatment of [[AML M3]] by [[all-trans retinoic acid]] causes the release of [[Auer rods]] and potentially might cause [[disseminted intravascular coagulation]] ([[DIC]]).  
The patient in this scenario is likely presenting with [[acute promyelocytic leukemia]] ([[APML]]) or [[AML M3]].  Symptoms of [[AML M3]] are typically unremitting fever with signs of [[pancytopenia]], such as [[anemia]] as manifested by pallor, [[thrombocytopenia]] as manifested by easy bruisibility and [[purpura]], and [[leucopenia]] as manifested by [[sore throat]], [[pneumonia]], or other infections.  On peripheral smear, [[AML M3]] is frequently characterized by [[Auer rods]].  The image above displays one circled [[Auer rod]], as well as several others that are not circled.  Treatment of [[AML M3]] by [[all-trans retinoic acid]] leads to the release of [[Auer rods]] and potentially results in [[disseminted intravascular coagulation]] ([[DIC]]).  
[[DIC]] is a complication of several diseases, including [[AML M3]]. In the latter, [[DIC]] occurs following treatment [[DIC]] is characterized by activation of the [[hemostasis]] system with release of [[tissue factor]] mostly from [[endothelial cells]].  Normally, the inhibitor system compensates for the tissue factor release, but as the injury persists, eventual consumption of inhibitors occurs and more coagulation ensues in a process called “[[consumptive coagulopathy]]”.  
[[DIC]], a complication of several diseases including [[AML M3]], occurs following treatment and is characterized by activation of the [[hemostasis]] system, with the release of [[tissue factor]] usually from [[endothelial cells]].  Normally, the inhibitor system compensates for the tissue factor release, but with the eventual consumption of inhibitors more coagulation ensues in a process called “[[consumptive coagulopathy]]”.  
   
   
As a result, the entire [[hemostasis]] pathway becomes unbalanced and breaks down. Symptoms of [[DIC]] include profuse bleeding with blood work-up revealing low [[fibrinogen]], with elevated levels of [[D-dimer]] and [[fibrinogen split products]] ([[FSP]]), suggesting the generation of [[plasmin]].   [[Consumptive coagulopathy]] is corrected by [[cryoprecipitate]], [[platelet]] concentrations, and [[fresh frozen plasma]] ([[FFP]]) to help reduce the tendency to bleed.
As a result, the entire [[hemostasis]] pathway becomes unbalanced and breaks down. [[DIC]] frequently manifests with profuse bleeding and upon blood work-up, low [[fibrinogen]] levels, elevated levels of [[D-dimer]], and [[fibrinogen split products]] ([[FSP]]), suggesting the generation of [[plasmin]]. [[Consumptive coagulopathy]] is corrected with [[cryoprecipitate]], [[platelet]] concentrations, and [[fresh frozen plasma]] ([[FFP]]), which reduces the tendency to bleed.


Educational Objective:
|EducationalObjectives= [[AML M3]] is frequently characterized by pancytopenia and fever, with a peripheral blood smear displaying plasma cells containing [[Auer rods]][[DIC]] is a common complication following treatment of [[AML M3]], due to the release of [[Auer rods]][[DIC]], a consumptive coagulopathy, is caused by the imbalance of the hemostasis and fibrinolytic systems.
AML M3 is characterized by pancytopenia and fever with peripheral blood smear showing plasma cells containing Auer rods.  DIC is a common complication following treatment of AML M3 due to release of Auer rods.  DIC is a consumptive coagulopathy that is caused by the imbalance of hemostasis and fibrinolytic pathway.
|References= Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci. 2000;13(4):239-45


Reference:
|AnswerA=Activation of hemostasis and fibrinolysis that leads to formation of thrombin and plasmin
Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci. 2000;13(4):239-45
|AnswerAExp=See explanation.
|AnswerA=Activation of hemostasis and fibrinolysis that lead to formation of thrombin and plasmin
|AnswerAExp=DIC is characterized by the activation of hemostasis and fibrinolysis that lead to formation of thrombin and plasmin.
|AnswerB=Autoimmune antibodies against platelets
|AnswerB=Autoimmune antibodies against platelets
|AnswerBExp=Idiopathic thrombocytopenic purpura (ITP) is characterized by autoimmune antibodies against platelets that typically occur following a viral illness.
|AnswerBExp=[[Idiopathic thrombocytopenic purpura]] (ITP), characterized by the presence of autoimmune antibodies against platelets, typically occurs following a viral illness.
|AnswerC=Systemic deposition of platelet thrombi with abundant von Willebrand factor (vWF) in arterioles and capillaries
|AnswerC=Systemic deposition of platelet thrombi with abundant von Willebrand factor (vWF) in arterioles and capillaries
|AnswerCExp=Thrombotic thrombocytopenic purpura (TTP) is characterized by the systemic deposition of platelet thrombi with abundant von Willebrand factor (vWF) in arterioles and capillaries.
|AnswerCExp=[[Thrombotic thrombocytopenic purpura]] (TTP) is characterized by the systemic deposition of [[platelet thrombi]] with abundant [[von Willebrand factor]] (vWF) in arterioles and capillaries.
|AnswerD=Increased ristocetin sensitivity
|AnswerD=Increased ristocetin sensitivity
|AnswerDExp=von Willebrand’s disease (vWD) is characterized by increased sensitivity to ristocetin.
|AnswerDExp=[[von Willebrand disease]] (vWD) is characterized by an increased sensitivity to ristocetin.
|AnswerE=Monoclonal gammopathy of undetermined significance
|AnswerE=Monoclonal gammopathy of undetermined significance
|AnswerEExp=Monoclonal gammopathy of undetermined significance (MGUS) is a hematologic condition that is characterized by the presence of monoclonal antibodies without having clinical symptoms, or radiological and laboratory signs.  The disease is similar to multiple myeloma (MM), but unlike MM, the number of monoclonal plasma cells in MGUS is lower constituting less than 10% of bone marrow biopsy findings.  MGUS requires no treatment.  Monitoring for the evolution of MGUS into MM is important because rate of MM development is approximately 1-2% in patients with MGUS.
|AnswerEExp=[[Monoclonal gammopathy of undetermined significance]] (MGUS), a hematologic condition, is characterized by the presence of monoclonal antibodies without clinical symptoms, or radiological and laboratory signs.  The disease is similar to multiple myeloma (MM), but the number of monoclonal plasma cells in MGUS is lower, constituting less than 10% of bone marrow biopsy findings.  MGUS requires no treatment, but the rate of MM development is approximately 1-2% in patients with MGUS.
|RightAnswer=A
|RightAnswer=A
|WBRKeyword=AML, M3, DIC, disseminated, intravascular, coagulation, disseminated intravascular coagulation, acute, myelocytic, leukemia, promyelocytic, acute myelocytic leukemia, acute promyelocytic leukemia, fever, monoclonal, gammopathy
|WBRKeyword=AML M3, DIC, disseminated intravascular coagulation, acute myelocytic leukemia, acute promyelocytic leukemia, monoclonal, gammopathy, cancer, fibrinogen,
|Approved=No
|Approved=Yes
}}
}}

Revision as of 19:04, 23 July 2014

 
Author [[PageAuthor::Rim Halaby, M.D. [1], (Reviewed by Alison Leibowitz)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pathology
Sub Category SubCategory::Hematology, SubCategory::Oncology
Prompt [[Prompt::A 24-year-old male patient to the physician’s office with complaints of fatigue, unremitting fever, and easy bruisability upon minor trauma. His vital signs demonstrate a temperature of 38.6 °C, heart rate of 98 beats per minute, and blood pressure measuring 116/82 mmHg. Upon physical examination, you observe pallor, bleeding gums, and purpura. An image of the patient’s peripheral blood smear is displayed below. Following the initiation of appropriate treatment, the patient suffers a complication. Which of the following best characterizes the patient’s complication?

]]

Answer A AnswerA::Activation of hemostasis and fibrinolysis that leads to formation of thrombin and plasmin
Answer A Explanation AnswerAExp::See explanation.
Answer B AnswerB::Autoimmune antibodies against platelets
Answer B Explanation [[AnswerBExp::Idiopathic thrombocytopenic purpura (ITP), characterized by the presence of autoimmune antibodies against platelets, typically occurs following a viral illness.]]
Answer C AnswerC::Systemic deposition of platelet thrombi with abundant von Willebrand factor (vWF) in arterioles and capillaries
Answer C Explanation [[AnswerCExp::Thrombotic thrombocytopenic purpura (TTP) is characterized by the systemic deposition of platelet thrombi with abundant von Willebrand factor (vWF) in arterioles and capillaries.]]
Answer D AnswerD::Increased ristocetin sensitivity
Answer D Explanation [[AnswerDExp::von Willebrand disease (vWD) is characterized by an increased sensitivity to ristocetin.]]
Answer E AnswerE::Monoclonal gammopathy of undetermined significance
Answer E Explanation [[AnswerEExp::Monoclonal gammopathy of undetermined significance (MGUS), a hematologic condition, is characterized by the presence of monoclonal antibodies without clinical symptoms, or radiological and laboratory signs. The disease is similar to multiple myeloma (MM), but the number of monoclonal plasma cells in MGUS is lower, constituting less than 10% of bone marrow biopsy findings. MGUS requires no treatment, but the rate of MM development is approximately 1-2% in patients with MGUS.]]
Right Answer RightAnswer::A
Explanation [[Explanation::

The patient in this scenario is likely presenting with acute promyelocytic leukemia (APML) or AML M3. Symptoms of AML M3 are typically unremitting fever with signs of pancytopenia, such as anemia as manifested by pallor, thrombocytopenia as manifested by easy bruisibility and purpura, and leucopenia as manifested by sore throat, pneumonia, or other infections. On peripheral smear, AML M3 is frequently characterized by Auer rods. The image above displays one circled Auer rod, as well as several others that are not circled. Treatment of AML M3 by all-trans retinoic acid leads to the release of Auer rods and potentially results in disseminted intravascular coagulation (DIC). DIC, a complication of several diseases including AML M3, occurs following treatment and is characterized by activation of the hemostasis system, with the release of tissue factor usually from endothelial cells. Normally, the inhibitor system compensates for the tissue factor release, but with the eventual consumption of inhibitors more coagulation ensues in a process called “consumptive coagulopathy”.

As a result, the entire hemostasis pathway becomes unbalanced and breaks down. DIC frequently manifests with profuse bleeding and upon blood work-up, low fibrinogen levels, elevated levels of D-dimer, and fibrinogen split products (FSP), suggesting the generation of plasmin. Consumptive coagulopathy is corrected with cryoprecipitate, platelet concentrations, and fresh frozen plasma (FFP), which reduces the tendency to bleed.
Educational Objective: AML M3 is frequently characterized by pancytopenia and fever, with a peripheral blood smear displaying plasma cells containing Auer rods. DIC is a common complication following treatment of AML M3, due to the release of Auer rods. DIC, a consumptive coagulopathy, is caused by the imbalance of the hemostasis and fibrinolytic systems.
References: Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci. 2000;13(4):239-45]]

Approved Approved::Yes
Keyword WBRKeyword::AML M3, WBRKeyword::DIC, WBRKeyword::disseminated intravascular coagulation, WBRKeyword::acute myelocytic leukemia, WBRKeyword::acute promyelocytic leukemia, WBRKeyword::monoclonal, WBRKeyword::gammopathy, WBRKeyword::cancer, WBRKeyword::fibrinogen
Linked Question Linked::
Order in Linked Questions LinkedOrder::